Form 4: Mira Pharmaceuticals Director Acquires Stock Options
SEC Form 4
Matthew Paul Del Giudice, a director of Mira Pharmaceuticals, acquired nonqualified stock options on March 25, 2024.
Summary
- On March 25, 2024, Matthew Paul Del Giudice, a director at Mira Pharmaceuticals, acquired 50,000 nonqualified stock options with an exercise price of $1.16.
- 25,000 of these options vested immediately, and the remaining 25,000 will vest on March 25, 2025.
- Following the transaction, Mr. Del Giudice also disposed of 25,000 derivative securities.
Sentiment
Score: 5
Explanation: The sentiment is neutral as it's a standard disclosure of stock option grants to a director.
Industry Context
This filing is a routine disclosure of insider transactions, which are common in publicly traded companies. It provides transparency into the actions of company insiders.
Stakeholder Impact
- The transaction could have a minor impact on shareholders by potentially diluting equity if the options are exercised in the future.
Key Dates
| Date | Description |
|---|---|
| 03/25/2024 | Date of transaction: Director acquired stock options; 25,000 options vested immediately |
| 03/25/2025 | Remaining 25,000 options vest |
| 03/25/2034 | Expiration date of the options |
| 03/27/2024 | Date of Form 4 filing |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.